Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Brand, Douglas; Tree, Alison; Ostler, Peter; van der Voet, H.; Loblaw, Andrew; Chu, William; Ford, Daniel; Tolan, Shaun; Jain, Suneil; S. Martin, Alexander; Staffurth, John; Camilleri, Philip; Kancherla, Kiran; Frew, J.; Chan, Andrew; S. Dayes, Ian; Henderson, Daniel; Brown, Stephanie; Cruickshank, Clare; Burnett, Stephanie; Duffton, Aileen; Griffin, Clare; Hinder, Victoria; Morrison, Kirsty; Naismith, Olivia; Hall, Emma; van As, Nicholas; Dodds, D.; Lartigau, Éric; E. Patton, Suzanne; Thompson, Alan; Winkler, Mathias; Wells, Paula; Lymberiou, Timothy; Saunders, Deanna; Vilarino-Varela, Maria; Vavassis, Peter; Tsakiridis, Theodoros; Carlson, R; Rodrigues, George; Tanguay, Jean-François; Iqbal, Shahid; Winkler, Mathias; C. Morgan, Scott; Mihai, Alina; Li, A; Din, Omar; Panadés, M.; Wade, Ros; Rimmer, Y.; Armstrong, John; Panadés, M.; Babu Oommen, Nikhil

doi:10.1016/s1470-2045(19)30569-8

Public

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Published in The Lancet Oncology • Sep 17, 2019

Authors:

Douglas Brand

Alison Tree

Peter Ostler

Abstract

BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute ...

Subject

Medicine

Radiation therapy

Prostate cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!